US › Healthcare

Lifecore Biomedical Inc. (LFCR)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$4.46+7.21%

Last close · 2026-09-17

Latest quarter · ended 2026-05-31

Revenue

$34.2M

Revenue YoY

-2.8%

Net profit

$-6.2M

EPS

$-0.19

EPS estimate

$-0.22

Net margin

-18.0%

EPS came in at -0.19 against a street estimate of -0.22 — a beat of 14.6%.

Key statistics

Market cap

$168.8M

Forward P/E

8.7

P/B

197.99

Book value

$-0.90

EPS (TTM)

$-1.27

52-week high

$8.98

52-week low

$3.63

50-day MA

$4.52

200-day MA

$5.81

Beta

1.08

Analyst view

Analysts rate Lifecore Biomedical Inc. a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $6.75.

Shareholding

Insiders

2.80%

Institutions

77.29%

Largest institutional holders

Fund	Stake
Wynnefield Capital Inc	12.42%
Legion Partners Asset Management, LLC	11.79%
Greenhaven Road Investment Management, L.P.	9.35%
325 Capital LLC	7.65%
BlackRock Inc	4.96%
Vanguard Capital Management, LLC	3.41%
Geode Capital Management, LLC	2.15%
Morgan Stanley - Brokerage Accounts	2.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lifecore Biomedical Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.